Influence of uraemia and haemodialysis on host defence and infection

Nephrology Dialysis Transplantation

Volumn 11, Issue 4, 1996, Pages 593-598

  Vanholder, R ^a   Van Loo, A ^a   Dhondt, A M ^a   De Smet, R ^a   Ringoir, S ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

HEMODIALYSIS; HOST RESISTANCE; IMMUNE SYSTEM; INFECTION; INFECTION RESISTANCE; MALNUTRITION; PRIORITY JOURNAL; SHORT SURVEY; UREMIA;

EID: 0029918417     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.ndt.a027346     Document Type: Short Survey

References (69)

1. Schena FP, Pertosa G. Fibronectin and the kidney. Nephron 1988; 48: 177-182
2. Peterson PK, Matzke G, Keane WF Current changes in the management of peritonitis in patients undergoing continuous ambulatory peritoneal dialysis. Rev Infect Dis 1987; 9: 604-612
3. Gordon DL, Rice JL, Avery VM. Surface phagocytosis and hostdefence in the peritoneal cavity during continuous ambulatory peritoneal dialysis. Eur J Clin Microbiol Infect Dis 1990; 9: 191-197
4. Stevens CE, Alter HJ, Taylor PE, Zang EA, Harley EJ, Szmuness W, and the dialysis vaccine trial study group. Hepatitis B vaccine in patients receiving hemodialysis. Immunogenicity and efficacy. N Engl J Med 1984; 311: 496-501
5. Fleming SJ, Moran DM, Cooksley WGE, Faoagoli JL. Poor response to a recombinant hepatitis B vaccine in dialysis patients. J Infect 1991; 22: 251-257
6. Köhler H, Arnold W, Renschin G, Dormeyer HH, Meyer zum Büschenfelde KH. Active hepatitis B vaccination of dialysis patients and medical staff. Kidney Int 1984; 25. 124-128
7. Benhamou E, Courouce AM, Jungers P et al. Hepatitis B vaccine: randomized trial of immunogenicity in hemodialysis patients. Clin Nephrol 1984; 21: 143-147
8. Sennesael JJ, Van der Niepen P, Verbeelen DL. Treatment with recombinant erythropoietin increases antibody titers after Hepatitis B vaccination in dialysis patients. Kidney Int 1991; 40: 121-128
9. Vanholder R, Ringoir S. Hemodiafiltration. Contrib Nephrol 1989; 69: 131-140
10. Malappioni M, Baldassari M, Saldini S, Radicioni R, Panichi N. Use of immunomodulators (thymopentine) in hepatitis B vaccine in elderly patients undergoing chronic hemodialysis. Nephron 1992; 61: 358-359 (Letter)
11. Dumann H, Meuer SC, Renschin G, Köhler H. Influence of thymopentin on antibody response, and monocyte and T cell function in hemodialysis patients who fail to respond to hepatitis B vaccination. Nephron 1990; 55: 136-140
12. Ringoir S, Van Landschoot N, De Smet R. Inhibition of phagocytosis by a middle molecular fraction from ultrafiltrate. Clin Nephrol 1980; 13: 109-112
13. Vanholder R, De Smet R, Jacobs V et al. Uraemic retention solutes depress polymorphonuclear response to phagocytosis. Nephrol Dial Transplant 1994; 9: 1271-1278
14. Vanholder R, Ringoir S. Infectious morbidity and defects of phagocytic function in end-stage renal disease: a review. J Am Soc Nephrol 1993; 3: 1541-1554
15. Hörl WH, Haag-Weber M, Georgopoulos A, Block LH. Physicochemical characterization of a polypeptide present in uremic serum that inhibits the biological activity of polymorphonuclear cells. Proc Natl Acad Sci USA 1990; 87. 6353-6357
16. 2-microglobulin. Nephrol Dial Transplant 1994; 9: 382-388
17. Vanholder R, De Smet R, Waterloos MA et al. Mechanisms of uremic inhibition of phagocyte reactive species production: characterization of the role of p-cresol. Kidney Int 1995; 47: 510-517
18. Witko V, Nguyen AT, Descamps-Latscha B. Microtiter plate assay for phagocyte-derived taurine-catecholamines. J Clin Lab Anal 1993; 6: 47-53
19. Thomas EL, Grisham MB, Jefferson MM. Myeloperoxidase-dependent effect of amines on functions of isolated neutrophils. J Clin Invest 1983; 72: 441-454
20. Vallance P, Leone A, Calver A, Collier J, Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992; 339: 572-575
21. Noris M, Benigni A, Boccardo P et al Enhanced nitric oxide synthesis in uremia: implications for platelet dysfunction and dialysis hypotension. Kidney Int 1993; 44: 445-450
22. Cantinieaux B, Boelaert J, Hariga C, Fondu P. Impaired neutrophil defense against Yersinia enterocolitica in patients with iron overload who are undergoing dialysis. J Lab Clin Med 1988; 111: 524-528
23. Boelaert JR, Daneels RF, Schurgers ML, Matthys EG, Gordts BZ, Van Landuyt HW. Iron overload in haemodialysis patients increases the risk of bacteraemia: a prospective study. Nephrol Dial Transplant 1990; 5: 130-134
24. Boelaert JR, Cantinieaux BF, Hariga CF, Fondu PG. Recombinant erythropoietin reverses polymorphonuclear granulocyte dysfunction in iron-overloaded dialysis patients. Nephrol Dial Transplant 1990; 5: 504-507
25. Veys N, Vanholder R, Ringoir S. Correction of deficient phagocytosis during erythropoietin (EPO) treatment in maintenance hemodialysis patients. Am J Kidney Dis 1992; 19: 358-363
26. Boelaert JR, Van Roost GF, Vergauwe PL, Verbanck JJ, De Vroey C, Segaert MF. The role of desferrioxamine in dialysis-associated mucormycosis: report of three cases and review of the literature. Clin Nephrol 1988; 29: 261-266
27. Vanholder R, Van Biesen W, Ringoir S. Contributing factors to the inhibition of phagocytosis in hemodialyzed patients. Kidney Int 1993; 44: 208-214
28. Collart FE, Dratwa M, Wittek M, Wens R. Effects of recombinant human erythropoietin on T lymphocyte subsets in hemodialysis patients. Trans Am Soc Artif Intern Organs 1990; 36: M219-223
29. Briggs WA, Pedersen MM, Mahajan SK, Sillix DH, Prasad AS, McDonald FD. Lymphocyte and granulocyte function in zinc-treated and zinc-deficient hemodialysis patients. Kidney Int 1982; 21: 827-832
30. Delafuente JC. Nutrients and immune responses. Rheum Dis Clin North Am 1991; 17. 203-212
31. Taccone-Gallucci M, Giardini O, Ausiello C et al Vitamin E supplementation in hemodialysis patients: effects on peripheral blood mononuclear cells lipid peroxidation and immune responses. Clin Nephrol 1986; 25: 81-86
32. Kriley M, Warady BA. Vitamin status of pediatric patients receiving long-term peritoneal dialysis. Am J Clin Nutr 1991; 53: 1476-1479
33. Provvedini DM, Tsoukas CD, Deftos LJ, Manolagas SC. 1,25-dihydroxyvitamin D3 receptors in human leukocytes. Science 1983; 221: 1181-1183
34. Duits AJ, Dinjati W, van de Winkel JGJ, Capel PJA. Synergism of interleukin 6 and 1a,25-dihydroxyvitamin D3 in induction of myeloid differentiation of human leukemic cell lines. J Leukocyte Biol 1992; 51: 237-243
35. Hsu CH, Vanholder R, Patel S, De Smet RR, Sandra P, Ringoir S. Subfractions in uremic plasma ultrafiltrate inhibit calcitriol metabolism. Kidney Int 1991; 40: 868-873
36. Hsu CH, Patel SR, Young EW, Vanholder R. Effects of purine derivatives on calcitriol metabolism in rats. Am J Physiol 1991; 260: F596-F601
37. 2)D in renal failure. J Am Soc Nephrol 1993; 4: 1035-1038
38. Hakim RM. Clinical implications of hemodialysis membrane biocompatibility. Kidney Int 1993; 44: 484-494
39. Vanholder R, Ringoir S, Dhondt A, Hakim R. Phagocytosis in uremic and hemodialysis patients: a prospective and cross sectional study. Kidney Int 1991; 39: 320-327
40. Himmelfarb J, Zaoui P, Hakim R. Modulation of granulocyte LAM-1 and MAC-1 during dialysis - A prospective, randomized controlled trial. Kidney Int 1992; 41: 388-395
41. Dhondt AM, Waterloos MA, Van Loo A, Ringoir S, Vanholder R. Effect of dialyzer biocompatibility on CD14-expression in resting and stimulated monocytes. J Am Soc Nephrol 1994; 4: 443 (abstract)
42. Himmelfarb J. Infection in hemodialysis patients: do dialysis membranes play a role. Semin Dial 1992; 5: 108-111
43. Levin NW, Zasuwa G, Dumler F. Effect of membrane type on causes of death in hemodialysis patients. J Am Soc Nephrol 1991; 2: 335 (abstract)
44. Hornberger JC, Chernew M, Petersen J, Garber AM. A multivariate analysis of mortality and hospital admissions with high-flux dialysis. J Am Soc Nephrol 1992; 3: 1227-1237
45. Maiorca R, Cancarini GC, Brunori G, Camerini C, Manili L. Morbidity and mortality of CAPD and hemodialysis. Kidney Int 1993; 43: S4-S15
46. Buggy BP, Schaberg DR, Swartz RD Intraleukocytic sequestration as a cause of persistent staphylococcus aureus peritonitis in continuous ambulatory peritoneal dialysis. Am J Med 1984; 76: 1035-1040
47. Vanholder R, Lameire N, De Smet R, Waterloos MA, Ringoir S. Disturbed host defense in the peritoneal cavity during CAPD: characterization of responsible factors in dwell fluid. J Am Soc Nephrol 1994; 4: 482 (Abstract)
48. Haag-Weber M, Mai B, Hörl WH. Impaired cellular host defence in peritoneal dialysis by two granulocyte inhibitory proteins. Nephrol Dial Transplant 1994; 9: 1769-1773
49. Jörres A, Topley N, Steenweg L, Müller C, Köttgen E, Gahl GM. Inhibition of cytokine synthesis by peritoneal dialysate persists throughout the CAPD cycle. Am J Nephrol 1992; 12: 80-85
50. Levy R, Klein J, Rubinek T, Alkan M, Shany S, Chaimovitz C. Diversity in peritoneal macrophage response of CAPD patients to 1,25-dihydroxyvitamin D3. Kidney Int 1990; 37: 1310-1315
51. Jörres A, Jörres D, Topley N, Gahl GM, Mahiout A. Leukotriene release from peripheral and peritoneal leukocytes following exposure to peritoneal dialysis solutions. Nephrol Dial Transplant 1991; 6: 495-501
52. Vanholder R, Hoenich N, Ringoir S. Morbidity and mortality of central venous catheter hemodialysis: a review of 10 years' experience. Nephron 1987; 7: 274-9
53. Kherlakian GM, Roedersheimer LR, Arbough JJ, Newmark KJ, King LR. Comparison of autologous fistula versus expanded polytetrafluoroethylene graft fistula for angioaccess in hemodialysis. Am J Surg 1986; 152: 238-242
54. Chow JW, Yu VL. Staphylococcus aureus nasal carriage in hemodialysis patients - its role in infection and approaches to prophylaxis. Arch Intern Med 1989; 149: 1258-1262
55. Swartz R, Messana J, Starmann B, Weber M, Reynolds J. Preventing Staphylocuccus aureus infection during chronic peritoneal dialysis. J Am Soc Nephrol 1991; 2: 1085-1091
56. Young GA, Kopple JD, Lindholm B et al. Nutritional assessment of continuous ambulatory peritoneal dialysis patients: an international study. Am J Kidney Dis 1991; 17: 462-471
57. Villa ML, Ferrario E, Bergamasco E, Bozzetti F, Cozzaglio L, Clerici E. Reduced natural killer cell activity and Il-2 production in malnourished cancer patients. Br J Cancer 1991; 63: 1010-1014
58. Redmond HP, Shou J, Kelly CJ et al. Immunosuppressive mechanisms in protein-calorie nutrition. Surgery 1991; 110: 311-317
59. Churchill DN, Taylor W, Cook RJ et al. Canadian hemodialysis morbidity study. Am J Kidney Dis 1992; 19: 214-234
60. Field CJ, Gougeon R, Marliss EB. Changes in circulating leukocytes and mitogen responses during very-low-energy all-protein reducing diets. Am J Clin Nutr 1991; 54: 123-129
61. Hauser WE, Remington JS. Effect of antibiotics on the immune response Am J Med 1982; 72: 711-716
62. Verpooten GA, D'Haese PC, Boelaert JR, Becaus I, Lamberts LV, De Broe ME. Pharmacokinetics of aluminoxamine and ferrioxamine and dose finding of desferrioxamine in haemodialysis patients. Nephrol Dial Transplant 1992; 7: 931-938
63. Schulman G, Fogo A, Badr K, Hakim R. Complement activation retards resolution of acute ischemic renal failure in the rat. Kidney Int 1991; 40: 1069-1074
64. Vanholder R, Van Landschoot N, Dagrosa E, Ringoir S. Cefodizime: a new cephalosporin with apparent immunestimulating properties in chronic renal failure. Nephrol Dial Transplant 1988; 3: 221-224
65. Vanholder R, Dagrosa E, Van Landschoot N, Waterloos MA, Ringoir S. Effect of antibiotics on phagocytosis-associated respiratory burst activity in uraemic patients on chronic haemodialysis: a comparison of cefodizime and cotrimoxazole. Nephron 1993; 63: 65-72
66. Cheeseman SH, Rubin RH, Stewart JA et al Controlled clinical trial of prophylactic human-leukocyte interferon in transplantation. N Engl J Med 1979; 300: 1346-1349
67. Quiroga JA, Castillo I, Porres JC et al. Recombinant gamma-interferon as adjuvant to hepatitis B vaccine in hemodialysis patients. Hepatology 1990; 12: 661-663
68. Knudsen F, Wantzin P, Rasmussen K et al. Hepatitis C in dialysis patients: relationship to blood transfusions, dialysis and liver disease. Kidney Int 1993; 43: 1353-1356
69. Kawano Y, Takaue Y, Motoyoshi K et al. Measurement of serum levels of macrophage colony-stimulating factor (M-CSF) in patients with uremia. Exp Hematol 1993; 21: 220-223